首页> 外文期刊>Clinical oncology >The impact of FDG PET on the management of occult primary head and neck tumours.
【24h】

The impact of FDG PET on the management of occult primary head and neck tumours.

机译:FDG PET对隐匿性原发性头颈部肿瘤治疗的影响。

获取原文
获取原文并翻译 | 示例
       

摘要

AIMS: The aim of this study was to investigate the impact of positron-emission tomography (PET) with 18F-labelled fluoro-2-deoxy-D-glucose (FDG) in the management of occult primary head and neck tumours. MATERIALS AND METHODS: We reviewed 16 patients with squamous cell carcinoma (SCC) and one patient with undifferentiated carcinoma of cervical lymph nodes (N1-4; N2a-9; N2b-2; N3-2). All patients had full clinical assessment, including examination under anaesthesia (EUA), with biopsy of all suspicious areas and random biopsies of sites likely to harbour an occult primary site. Nine patients underwent magnetic resonance imaging (MRI) of the head and neck, three underwent computed tomography (CT) and five underwent both CT and MRI. None of these studies were able to locate a primary tumour. Patients received 350 MBq FDG intravenously. Emission transmission scans of the extra-cranial head, neck and thorax were obtained using an ECAT Exact 47 at least 60 min after injection. The images were interpreted by the same radiologist experienced in PET, independent of the final outcome. The influence of FDG PET on management was assessed on review of the patients' notes after treatment or when treatment had been deemed unnecessary. RESULTS: FDG PET suggested a primary site in eight of the 17 patients (tongue base 5; nasopharynx 1; tonsil 1: supraglottis 1). Pathological confirmation was obtained in four patients and one patient died of progressive disease at the primary site. In nine patients, the primary site was not identified on FDG PET. In six of these patients, no primary site was found during follow-up (range 8-36 months: mean 20 months). One patient died before treatment commenced, and there were two histologically confirmed false-negative FDG PET results: one tonsil SCC and one lateral pharyngeal wall SCC. FDG PET affected treatment plans in nine of the 17 (53%) patients in whom a primary site was suggested (altered radiotherapy plan 6; radiotherapy with curative intent to palliative radiotherapy 1; radiotherapy to surgery and post-operative radiotherapy 1), and in one patient where no occult primary was localised (radiotherapy to surgery 1). FDG PET had a sensitivity, specificity, positive and negative predictive value of 62%, 66%, 62% and 62%, respectively.
机译:目的:本研究的目的是研究正电子发射断层扫描(PET)与18F标记的氟-2-脱氧-D-葡萄糖(FDG)在隐匿性原发性头颈部肿瘤治疗中的作用。材料与方法:我们回顾了16例鳞状细胞癌(SCC)和1例未分化的宫颈淋巴结癌(N1-4; N2a-9; N2b-2; N3-2)。所有患者均进行了全面的临床评估,包括在麻醉(EUA)下进行检查,并对所有可疑区域进行活检,并对可能隐匿有原发部位的部位进行随机活检。 9例患者进行了头部和颈部的磁共振成像(MRI),其中3例进行了计算机断层扫描(CT),其中5例同时进行了CT和MRI检查。这些研究均未找到原发肿瘤。患者静脉接受350 MBq FDG。注射后至少60分钟,使用ECAT Exact 47获得颅外头部,颈部和胸部的发射透射扫描。图像由具有PET经验的同一位放射线医师解释,与最终结果无关。在治疗后或认为不需要治疗时,应通过回顾患者的笔记来评估FDG PET对治疗的影响。结果:FDG PET提示17例患者中有8例为原发部位(舌基5;鼻咽1;扁桃体1:眼睑上方1)。在四名患者中获得了病理证实,一名患者在原发部位死于进行性疾病。在9例患者中,FDG PET上未发现主要部位。在这些患者中有6例在随访期间未发现原发部位(范围8-36个月:平均20个月)。一名患者在开始治疗前死亡,并且在组织学上证实有两种假阴性的FDG PET结果:一例扁桃体鳞状上皮癌和一例咽旁侧壁SCC。 FDG PET影响了建议原发部位的17例患者中的9例(53%)的治疗计划(改变的放疗计划6;针对姑息性放疗的治愈性放疗1;对手术和术后放疗的放射治疗1),以及一名没有隐匿性原发灶的患者(手术放疗1)。 FDG PET的敏感性,特异性,阳性和阴性预测值分别为62%,66%,62%和62%。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号